Competition policy: The European Commission sends a DNA sequencing company a statement of objections with instructions on how to unravel its - prohibited - merger with another DNA sequencing company (Illumina / Grail)

KEYWORDS
Reference

Eur. Comm., Dec. 5th, 2022, press release IP/22/7403, Mergers: The Commission adopts a Statement of Objections outlining measures to unwind Illumina’s blocked acquisition of GRAIL

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. On December 5, 2022, the European Commission announced that it had issued a statement of objections to Illumina and Grail setting forth the measures necessary to unwind Illumina's acquisition of Grail, following the prohibition of the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

This document is protected by copyright laws and international copyright treaties. Non-authorised use of this document constitutes a violation of the publisher's rights and may be punished by up to 3 years imprisonment and up to a € 300 000 fine (Art. L 335-2 Code de la Propriété Intellectuelle). Personal use of this document is authorised within the limits of Art. L 122-5 CPI and DRM protection.

PDF Version

Author

  • L’actu-concurrence (Paris)
    France 4522 contributions 1119110 visits

Quotation

Alain Ronzano, Competition policy: The European Commission sends a DNA sequencing company a statement of objections with instructions on how to unravel its - prohibited - merger with another DNA sequencing company (Illumina / Grail), 5 December 2022, Concurrences N° 1-2023, Art. N° 110046, www.concurrences.com

Visites 168

All reviews